STOCK TITAN

[S-8] Brainstorm Cell Therapeutics Inc. Employee Benefit Plan Registration

Filing Impact
(No impact)
Filing Sentiment
(Neutral)
Form Type
S-8
Rhea-AI Filing Summary

On 3 July 2025, ContextLogic Inc. (ticker WISH) filed an 8-K announcing a Second Amended & Restated Agreement and Plan of Reorganization. The sole material change responds to Institutional Shareholder Services’ (ISS) recommendation that shareholders vote against the original proposal: the 4.9% Transfer Restrictions on post-reorganization stock will now expire no later than the third anniversary of the reorganization’s effectiveness. The revised definition is embedded in Article XIV of Easter Parent, Inc.’s certificate of incorporation.

The amendment, to be voted on at the 10 July 2025 Annual Meeting, will be deemed approved if shareholders vote “FOR” the Reorganization Proposal. No economic terms, consideration, or capital structure elements were modified. ContextLogic also intends to distribute additional shareholder communications (Exhibit 99.1) urging support.

Key investor takeaways

  • The time-limited sunset directly removes ISS’s primary objection, increasing the likelihood of a favorable proxy-adviser recommendation and passage.
  • Liquidity concerns are partially mitigated; holders may exceed 4.9% ownership after three years.
  • The filing contains no new financial metrics; therefore near-term valuation remains unchanged.
  • Full texts of the amended agreement (Exhibit 2.1) and certificate (Exhibit 3.1) are incorporated by reference.

Il 3 luglio 2025, ContextLogic Inc. (ticker WISH) ha depositato un 8-K annunciando un Secondo Accordo Modificato e Ristabilito e Piano di Riorganizzazione. L'unica modifica sostanziale risponde alla raccomandazione di Institutional Shareholder Services (ISS) che invitava gli azionisti a votare contro la proposta originale: le Restrizioni di Trasferimento del 4,9% sulle azioni post-riorganizzazione scadranno ora non oltre il terzo anniversario dell'efficacia della riorganizzazione. La definizione rivista è incorporata nell'Articolo XIV dello statuto di Easter Parent, Inc.

La modifica, che sarà votata durante la Assemblea Annuale del 10 luglio 2025, sarà considerata approvata se gli azionisti voteranno “A FAVORE” della Proposta di Riorganizzazione. Non sono stati modificati termini economici, considerazioni o elementi della struttura del capitale. ContextLogic intende inoltre distribuire ulteriori comunicazioni agli azionisti (Allegato 99.1) per sollecitare il sostegno.

Punti chiave per gli investitori

  • La scadenza temporanea elimina direttamente l'obiezione principale di ISS, aumentando la probabilità di una raccomandazione favorevole da parte del consulente per il voto e l'approvazione.
  • Le preoccupazioni sulla liquidità sono parzialmente mitigate; i detentori potranno superare il 4,9% di proprietà dopo tre anni.
  • Il deposito non contiene nuove metriche finanziarie; pertanto la valutazione a breve termine rimane invariata.
  • I testi completi dell'accordo modificato (Allegato 2.1) e dello statuto (Allegato 3.1) sono incorporati per riferimento.

El 3 de julio de 2025, ContextLogic Inc. (símbolo WISH) presentó un 8-K anunciando un Segundo Acuerdo Modificado y Reexpresado y Plan de Reorganización. El único cambio material responde a la recomendación de Institutional Shareholder Services (ISS) para que los accionistas votaran en contra de la propuesta original: las Restricciones de Transferencia del 4,9% sobre las acciones posteriores a la reorganización expirarán a más tardar en el tercer aniversario de la efectividad de la reorganización. La definición revisada está incorporada en el Artículo XIV del certificado de incorporación de Easter Parent, Inc.

La enmienda, que se votará en la Reunión Anual del 10 de julio de 2025, se considerará aprobada si los accionistas votan “A FAVOR” de la Propuesta de Reorganización. No se modificaron términos económicos, consideraciones ni elementos de la estructura de capital. ContextLogic también planea distribuir comunicaciones adicionales a los accionistas (Exhibición 99.1) para fomentar el apoyo.

Puntos clave para inversionistas

  • La limitación temporal elimina directamente la objeción principal de ISS, aumentando la probabilidad de una recomendación favorable del asesor de voto y la aprobación.
  • Las preocupaciones sobre liquidez se mitigan parcialmente; los tenedores podrán superar el 4,9% de propiedad después de tres años.
  • La presentación no contiene nuevas métricas financieras; por lo tanto, la valoración a corto plazo permanece sin cambios.
  • Los textos completos del acuerdo enmendado (Exhibición 2.1) y del certificado (Exhibición 3.1) están incorporados por referencia.

2025년 7월 3일, ContextLogic Inc.(티커 WISH)는 8-K 보고서를 제출하며 두 번째 수정 및 재작성된 합의서 및 재조직 계획을 발표했습니다. 유일한 중요한 변경 사항은 Institutional Shareholder Services(ISS)가 주주들에게 원래 제안에 대해 반대 투표를 권고한 데 대한 대응으로, 재조직 후 주식에 대한 4.9% 양도 제한이 재조직 발효일로부터 최대 3주년까지 만료되도록 수정되었습니다. 개정된 정의는 Easter Parent, Inc.의 정관 제14조에 포함되어 있습니다.

이 개정안은 2025년 7월 10일 연례 주주총회에서 투표될 예정이며, 주주들이 재조직 제안에 대해 “찬성” 투표할 경우 승인된 것으로 간주됩니다. 경제적 조건, 대가 또는 자본 구조 요소는 변경되지 않았습니다. ContextLogic은 추가 주주 커뮤니케이션(증거물 99.1)을 배포하여 지지를 촉구할 계획입니다.

주요 투자자 요점

  • 기간 제한 종료 조항은 ISS의 주요 반대를 직접 해소하여 우호적인 의결권 자문 추천과 통과 가능성을 높입니다.
  • 유동성 우려가 부분적으로 완화되며, 보유자는 3년 후 4.9% 이상의 지분을 가질 수 있습니다.
  • 이번 제출에는 새로운 재무 지표가 포함되어 있지 않으므로 단기 가치 평가는 변함이 없습니다.
  • 수정된 합의서 전문(증거물 2.1)과 정관(증거물 3.1)이 참고 문헌으로 포함되어 있습니다.

Le 3 juillet 2025, ContextLogic Inc. (symbole WISH) a déposé un 8-K annonçant un Deuxième Accord Modifié et Réexprimé et Plan de Réorganisation. Le seul changement matériel répond à la recommandation d’Institutional Shareholder Services (ISS) invitant les actionnaires à voter contre la proposition initiale : les restrictions de transfert de 4,9 % sur les actions post-réorganisation expireront désormais au plus tard à la troisième année suivant la prise d’effet de la réorganisation. La définition révisée est intégrée à l’article XIV des statuts d’Easter Parent, Inc.

L’amendement, soumis au vote lors de l’Assemblée générale annuelle du 10 juillet 2025, sera considéré comme approuvé si les actionnaires votent « POUR » la proposition de réorganisation. Aucun terme économique, considération ou élément de la structure du capital n’a été modifié. ContextLogic prévoit également de diffuser des communications supplémentaires aux actionnaires (Exhibit 99.1) pour encourager le soutien.

Points clés pour les investisseurs

  • La limitation dans le temps supprime directement l’objection principale d’ISS, augmentant la probabilité d’une recommandation favorable du conseiller en vote et de l’adoption.
  • Les préoccupations liées à la liquidité sont partiellement atténuées ; les détenteurs pourront dépasser 4,9 % de détention après trois ans.
  • Le dépôt ne contient aucune nouvelle donnée financière ; la valorisation à court terme reste donc inchangée.
  • Les textes complets de l’accord modifié (Exhibit 2.1) et des statuts (Exhibit 3.1) sont incorporés par référence.

Am 3. Juli 2025 reichte ContextLogic Inc. (Ticker WISH) ein 8-K ein und kündigte eine Zweite geänderte und neu formulierte Vereinbarung und Reorganisationsplan an. Die einzige wesentliche Änderung reagiert auf die Empfehlung von Institutional Shareholder Services (ISS), dass Aktionäre gegen den ursprünglichen Vorschlag stimmen sollten: Die 4,9%igen Übertragungsbeschränkungen auf Aktien nach der Reorganisation werden nun spätestens am dritten Jahrestag der Wirksamkeit der Reorganisation ablaufen. Die überarbeitete Definition ist in Artikel XIV der Satzung von Easter Parent, Inc. verankert.

Die Änderung, über die auf der Hauptversammlung am 10. Juli 2025 abgestimmt wird, gilt als genehmigt, wenn die Aktionäre für den Reorganisationsvorschlag stimmen. Wirtschaftliche Bedingungen, Gegenleistungen oder Kapitalstrukturelemente wurden nicht geändert. ContextLogic plant außerdem, zusätzliche Aktionärskommunikationen (Anlage 99.1) zu verteilen, um Unterstützung zu fördern.

Wichtige Erkenntnisse für Investoren

  • Die zeitlich begrenzte Auslaufregelung beseitigt direkt den Hauptvorbehalt von ISS und erhöht die Wahrscheinlichkeit einer positiven Empfehlung des Proxy-Beraters und der Annahme.
  • Liquiditätsbedenken werden teilweise gemindert; Inhaber können nach drei Jahren mehr als 4,9% Eigentum halten.
  • Die Einreichung enthält keine neuen finanziellen Kennzahlen; daher bleibt die kurzfristige Bewertung unverändert.
  • Die vollständigen Texte der geänderten Vereinbarung (Anlage 2.1) und der Satzung (Anlage 3.1) sind durch Verweis aufgenommen.
Positive
  • Transfer restrictions now automatically expire after three years, directly addressing ISS’s objection and improving likelihood of shareholder approval.
  • Boards of all parties swiftly amended the agreement, demonstrating responsiveness to governance feedback and reducing execution risk.
Negative
  • Ownership is still capped at 4.9% until the three-year sunset, which may deter strategic investors and limit liquidity in the near term.
  • No additional financial or valuation data were provided, leaving investors without updated economic context for the reorganization.

Insights

TL;DR Time-boxed transfer cap removes ISS hurdle, materially improving governance optics and passage odds—net positive, no financial dilution.

Detail: ISS’s “against” recommendation threatened the reorganization vote. By adding a hard three-year sunset, the board demonstrates responsiveness to shareholder-advisory concerns, aligning protective tax provisions with market-standard timelines. This should shift ISS (and Glass Lewis) to a neutral or supportive stance, materially increasing the probability that retail and indexed investors back the deal. Because no valuation terms changed, upside is chiefly in smoothing the transaction path rather than altering cash flows. Risk: transfer limits persist for three years, still constraining block accumulations and possibly depressing liquidity in the interim.

TL;DR Structural tweak is procedural; economic deal terms unchanged—impact modest but directionally positive.

The amendment is narrowly scoped, leaving consideration, exchange ratios, and strategic rationale intact. As such, deal economics and projected synergies stay neutral. However, mitigating governance friction lowers execution risk, a meaningful benefit in small-cap transactions where failed votes can be costly. No new cost disclosures or financing updates were provided, so overall investor value remains driven by previously disclosed metrics.

Il 3 luglio 2025, ContextLogic Inc. (ticker WISH) ha depositato un 8-K annunciando un Secondo Accordo Modificato e Ristabilito e Piano di Riorganizzazione. L'unica modifica sostanziale risponde alla raccomandazione di Institutional Shareholder Services (ISS) che invitava gli azionisti a votare contro la proposta originale: le Restrizioni di Trasferimento del 4,9% sulle azioni post-riorganizzazione scadranno ora non oltre il terzo anniversario dell'efficacia della riorganizzazione. La definizione rivista è incorporata nell'Articolo XIV dello statuto di Easter Parent, Inc.

La modifica, che sarà votata durante la Assemblea Annuale del 10 luglio 2025, sarà considerata approvata se gli azionisti voteranno “A FAVORE” della Proposta di Riorganizzazione. Non sono stati modificati termini economici, considerazioni o elementi della struttura del capitale. ContextLogic intende inoltre distribuire ulteriori comunicazioni agli azionisti (Allegato 99.1) per sollecitare il sostegno.

Punti chiave per gli investitori

  • La scadenza temporanea elimina direttamente l'obiezione principale di ISS, aumentando la probabilità di una raccomandazione favorevole da parte del consulente per il voto e l'approvazione.
  • Le preoccupazioni sulla liquidità sono parzialmente mitigate; i detentori potranno superare il 4,9% di proprietà dopo tre anni.
  • Il deposito non contiene nuove metriche finanziarie; pertanto la valutazione a breve termine rimane invariata.
  • I testi completi dell'accordo modificato (Allegato 2.1) e dello statuto (Allegato 3.1) sono incorporati per riferimento.

El 3 de julio de 2025, ContextLogic Inc. (símbolo WISH) presentó un 8-K anunciando un Segundo Acuerdo Modificado y Reexpresado y Plan de Reorganización. El único cambio material responde a la recomendación de Institutional Shareholder Services (ISS) para que los accionistas votaran en contra de la propuesta original: las Restricciones de Transferencia del 4,9% sobre las acciones posteriores a la reorganización expirarán a más tardar en el tercer aniversario de la efectividad de la reorganización. La definición revisada está incorporada en el Artículo XIV del certificado de incorporación de Easter Parent, Inc.

La enmienda, que se votará en la Reunión Anual del 10 de julio de 2025, se considerará aprobada si los accionistas votan “A FAVOR” de la Propuesta de Reorganización. No se modificaron términos económicos, consideraciones ni elementos de la estructura de capital. ContextLogic también planea distribuir comunicaciones adicionales a los accionistas (Exhibición 99.1) para fomentar el apoyo.

Puntos clave para inversionistas

  • La limitación temporal elimina directamente la objeción principal de ISS, aumentando la probabilidad de una recomendación favorable del asesor de voto y la aprobación.
  • Las preocupaciones sobre liquidez se mitigan parcialmente; los tenedores podrán superar el 4,9% de propiedad después de tres años.
  • La presentación no contiene nuevas métricas financieras; por lo tanto, la valoración a corto plazo permanece sin cambios.
  • Los textos completos del acuerdo enmendado (Exhibición 2.1) y del certificado (Exhibición 3.1) están incorporados por referencia.

2025년 7월 3일, ContextLogic Inc.(티커 WISH)는 8-K 보고서를 제출하며 두 번째 수정 및 재작성된 합의서 및 재조직 계획을 발표했습니다. 유일한 중요한 변경 사항은 Institutional Shareholder Services(ISS)가 주주들에게 원래 제안에 대해 반대 투표를 권고한 데 대한 대응으로, 재조직 후 주식에 대한 4.9% 양도 제한이 재조직 발효일로부터 최대 3주년까지 만료되도록 수정되었습니다. 개정된 정의는 Easter Parent, Inc.의 정관 제14조에 포함되어 있습니다.

이 개정안은 2025년 7월 10일 연례 주주총회에서 투표될 예정이며, 주주들이 재조직 제안에 대해 “찬성” 투표할 경우 승인된 것으로 간주됩니다. 경제적 조건, 대가 또는 자본 구조 요소는 변경되지 않았습니다. ContextLogic은 추가 주주 커뮤니케이션(증거물 99.1)을 배포하여 지지를 촉구할 계획입니다.

주요 투자자 요점

  • 기간 제한 종료 조항은 ISS의 주요 반대를 직접 해소하여 우호적인 의결권 자문 추천과 통과 가능성을 높입니다.
  • 유동성 우려가 부분적으로 완화되며, 보유자는 3년 후 4.9% 이상의 지분을 가질 수 있습니다.
  • 이번 제출에는 새로운 재무 지표가 포함되어 있지 않으므로 단기 가치 평가는 변함이 없습니다.
  • 수정된 합의서 전문(증거물 2.1)과 정관(증거물 3.1)이 참고 문헌으로 포함되어 있습니다.

Le 3 juillet 2025, ContextLogic Inc. (symbole WISH) a déposé un 8-K annonçant un Deuxième Accord Modifié et Réexprimé et Plan de Réorganisation. Le seul changement matériel répond à la recommandation d’Institutional Shareholder Services (ISS) invitant les actionnaires à voter contre la proposition initiale : les restrictions de transfert de 4,9 % sur les actions post-réorganisation expireront désormais au plus tard à la troisième année suivant la prise d’effet de la réorganisation. La définition révisée est intégrée à l’article XIV des statuts d’Easter Parent, Inc.

L’amendement, soumis au vote lors de l’Assemblée générale annuelle du 10 juillet 2025, sera considéré comme approuvé si les actionnaires votent « POUR » la proposition de réorganisation. Aucun terme économique, considération ou élément de la structure du capital n’a été modifié. ContextLogic prévoit également de diffuser des communications supplémentaires aux actionnaires (Exhibit 99.1) pour encourager le soutien.

Points clés pour les investisseurs

  • La limitation dans le temps supprime directement l’objection principale d’ISS, augmentant la probabilité d’une recommandation favorable du conseiller en vote et de l’adoption.
  • Les préoccupations liées à la liquidité sont partiellement atténuées ; les détenteurs pourront dépasser 4,9 % de détention après trois ans.
  • Le dépôt ne contient aucune nouvelle donnée financière ; la valorisation à court terme reste donc inchangée.
  • Les textes complets de l’accord modifié (Exhibit 2.1) et des statuts (Exhibit 3.1) sont incorporés par référence.

Am 3. Juli 2025 reichte ContextLogic Inc. (Ticker WISH) ein 8-K ein und kündigte eine Zweite geänderte und neu formulierte Vereinbarung und Reorganisationsplan an. Die einzige wesentliche Änderung reagiert auf die Empfehlung von Institutional Shareholder Services (ISS), dass Aktionäre gegen den ursprünglichen Vorschlag stimmen sollten: Die 4,9%igen Übertragungsbeschränkungen auf Aktien nach der Reorganisation werden nun spätestens am dritten Jahrestag der Wirksamkeit der Reorganisation ablaufen. Die überarbeitete Definition ist in Artikel XIV der Satzung von Easter Parent, Inc. verankert.

Die Änderung, über die auf der Hauptversammlung am 10. Juli 2025 abgestimmt wird, gilt als genehmigt, wenn die Aktionäre für den Reorganisationsvorschlag stimmen. Wirtschaftliche Bedingungen, Gegenleistungen oder Kapitalstrukturelemente wurden nicht geändert. ContextLogic plant außerdem, zusätzliche Aktionärskommunikationen (Anlage 99.1) zu verteilen, um Unterstützung zu fördern.

Wichtige Erkenntnisse für Investoren

  • Die zeitlich begrenzte Auslaufregelung beseitigt direkt den Hauptvorbehalt von ISS und erhöht die Wahrscheinlichkeit einer positiven Empfehlung des Proxy-Beraters und der Annahme.
  • Liquiditätsbedenken werden teilweise gemindert; Inhaber können nach drei Jahren mehr als 4,9% Eigentum halten.
  • Die Einreichung enthält keine neuen finanziellen Kennzahlen; daher bleibt die kurzfristige Bewertung unverändert.
  • Die vollständigen Texte der geänderten Vereinbarung (Anlage 2.1) und der Satzung (Anlage 3.1) sind durch Verweis aufgenommen.

 

As filed with the Securities and Exchange Commission on July 3, 2025


Registration No. 333-       

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

 

FORM S-8

REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933

 

 

BRAINSTORM CELL THERAPEUTICS INC.

(Exact name of registrant as specified in its charter)

 

 

Delaware 20-7273918

(State or other jurisdiction of

incorporation or organization)

(I.R.S. Employer

Identification No.)

 

1325 Avenue of Americas, 28th Floor, New York, NY, 10019
(Address of Principal Executive Offices, Zip Code)

 

2014 Stock Incentive Plan

2014 Global Share Option Plan

(Full title of the plan)

 

Chaim Lebovits

President and Chief Executive Officer

Brainstorm Cell Therapeutics Inc.

1325 Avenue of Americas, 28th Floor

New York, NY 10019

(Name and address of agent for service)

 

(201) 488-0460

(Telephone number, including area code, of agent for service)

 

 

Copies to:

 

Mitchell S. Bloom, Esq.

Mayan Katz, Esq.

Goodwin Procter LLP

100 Northern Ave

Boston, Massachusetts 02210

(617) 570-1000

 

 

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

 

Large accelerated filer   ¨   Accelerated filer   ¨
       
Non-accelerated filer   x   Smaller reporting company   x
       
        Emerging growth company   ¨

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 7(a)(2)(B) of the Securities Act. ¨

 

 

 

EXPLANATORY NOTE

 

Pursuant to General Instruction E to Form S-8, this Registration Statement on Form S-8 (this “Registration Statement”) is being filed to register an additional 2,533,333 shares of common stock, par value $0.00005 per share (“Common Stock”), of Brainstorm Cell Therapeutics Inc. (the “Registrant”) reserved under the Registrant’s 2014 Stock Incentive Plan and the 2014 Global Share Option Plan, each as amended through June 25, 2025 (as amended, collectively, the “2014 Plans”), including (i) additional 533, 333 shares of Common Stock (as adjusted to reflect the reverse stock split effected in October 2024) reserved under the 2014 Plans pursuant to the amendments thereto adopted by the stockholders on September 16, 2024, and (ii) additional 2,000,000 shares of Common Stock reserved under the 2014 Plans pursuant to the amendments thereto adopted by the stockholders on June 25, 2025. This Registration Statement registers additional securities of the same class as other securities of the Registrant for which the registration statements filed on Form S-8 relating to the 2014 Plans (File No. 333-198391, File No. 333-213714, File No. 333-228981 and File No. 333-261598) of the Registrant are effective. The information contained in the Registrant’s registration statements on Form S-8 relating to the 2014 Plans (File No. 333-198391, File No. 333-213714, File No. 333-228981 and File No. 333-261598) is hereby incorporated by reference pursuant to General Instruction E of Form S-8, except with respect to Item 8. Exhibits thereof.

 

 

 

Part II

 

INFORMATION REQUIRED IN THE REGISTRATION STATEMENT

 

 

 

Item 8. Exhibits.

 

The exhibits listed on the Exhibit Index immediately preceding such exhibits are filed as part of this Registration Statement, and the contents of the Exhibit Index are incorporated herein by reference.

 

EXHIBIT INDEX

 

            Incorporated by Reference
Exhibit
Number
  Exhibit Description   Filed
Herewith
  Form   SEC File /
Registration
Number
      Exhibit   Filing Date
                           
4.1   Certificate of Incorporation of Brainstorm Cell Therapeutics Inc.       Definitive Schedule 14A   333-61610       Appendix B   11/20/2006
4.2   Certificate of Amendment of Certificate of Incorporation of Brainstorm Cell Therapeutics Inc. dated September 15, 2014.       8-K   000-54365       3.1   09/16/2014
4.3   Certificate of Amendment of Certificate of Incorporation of Brainstorm Cell Therapeutics Inc. dated August 31, 2015.       8-K   001-366641     3.1   09/04/2015
4.4   Certificate of Amendment of Certificate of Incorporation of Brainstorm Cell Therapeutics Inc., dated September 16, 2024.       8-K   001-366641       3.1   09/16/2024
4.5   Certificate of Amendment of Certificate of Incorporation of Brainstorm Cell Therapeutics Inc., dated September 30, 2024.       8-K   001-366641       3.1   10/01/2024
4.6   ByLaws of Brainstorm Cell Therapeutics Inc.        Definitive Schedule 14A   333-61610       Appendix C   11/20/2006
4.7   Amendment No. 1 to ByLaws of Brainstorm Cell Therapeutics Inc., dated as of March 21, 2007.       8-K   333-61610       3.1   03/27/2007
4.8   Amendment No. 2 to the Bylaws of Brainstorm Cell Therapeutics Inc., dated as of April 20, 2025       8-K   333-61610       3.1   04/21/2025
5.1   Opinion of Goodwin Procter LLP   X                    
23.1   Consent of Goodwin Procter LLP (included in opinion of counsel filed as Exhibit 5.1)   X                    
23.2   Consent of Brightman Almagor Zohar & Co., a Firm in the Deloitte Global Network.   X                    
24   Power of Attorney to file future amendments (set forth on the signature page of this Registration Statement)   X                    

 

 

 

99.1   Brainstorm Cell Therapeutics Inc. 2014 Stock Incentive Plan       8-K   000-54365       10.1   08/15/2014
99.2   Amendment No. 1 to the Brainstorm Cell Therapeutics Inc. 2014 Stock Incentive Plan       Definitive Schedule 14A   000-36641       Appendix A   05/11/2016
99.3   Amendment No. 2 to the Brainstorm Cell Therapeutics Inc. 2014 Stock Incentive Plan       8-K   000-36641       10.1   11/30/2018
99.4   Amendment No. 3 to the Brainstorm Cell Therapeutics Inc. 2014 Stock Incentive Plan       Definitive Schedule 14A   000-36641       Appendix A   10/01/2020
99.5   Amendment No. 4 to the Brainstorm Cell Therapeutics Inc. 2014 Stock Incentive Plan       8-K   000-36641       10.5   09/16/2024
99.6   Amendment No. 5 to the Brainstorm Cell Therapeutics Inc. 2014 Stock Incentive Plan       8-K   000-36641       10.6   06/25/2025
99.7   Brainstorm Cell Therapeutics Inc. 2014 Global Share Option Plan       8-K   000-54365       10.2   08/15/2014
99.8   Amendment No. 1 to Brainstorm Cell Therapeutics Inc. 2014 Global Share Option Plan       Definitive Schedule 14A   000-36641       Appendix B   05/11/2016
99.9   Amendment No. 2 to Brainstorm Cell Therapeutics Inc. 2014 Global Share Option Plan       8-K   000-36641       10.2   11/30/2018
99.10   Amendment No. 3 to Brainstorm Cell Therapeutics Inc. 2014 Global Share Option Plan       Definitive Schedule 14A   000-36641       Appendix B   10/01/2020
99.11   Amendment No. 4 to Brainstorm Cell Therapeutics Inc. 2014 Global Share Option Plan       8-K   000-36641       10.10   09/16/2024
99.12   Amendment No. 5 to Brainstorm Cell Therapeutics Inc. 2014 Global Share Option Plan       8-K   000-36641       10.12   06/25/2025
107   Filing Fee table   X                    

 

 

 

SIGNATURES

 

Pursuant to the requirements of the Securities Act of 1933, the Registrant certifies that it has reasonable grounds to believe that it meets all of the requirements for filing on Form S-8 and has duly caused this Registration Statement to be signed on its behalf by the undersigned, thereunto duly authorized, in City of New York, State of New York, on July 3, 2025.

 

  BRAINSTORM CELL THERAPEUTICS INC.
     
  By: /s/ Chaim Lebovits
    Chaim Lebovits
    President and Chief Executive Officer

 

Each person whose signature appears below constitutes and appoints Chaim Lebovits, Uri Yablonka and Alla Patlis, and each of them singly, his or her true and lawful attorneys-in-fact and agents, with full power of substitution and resubstitution in each of them singly, for him or her and in his or her name, place and stead, and in any and all capacities, to sign any and all amendments (including post-effective amendments) to this Registration Statement and to file the same, with all exhibits thereto and other documents in connection therewith, with the Securities and Exchange Commission, granting to the attorneys-in-fact and agents, and each of them, full power and authority to do and perform each and every act and thing requisite or necessary to be done in or about the premises, as full to all intents and purposes as he or she might or could do in person, hereby ratifying and confirming all that the attorneys-in-fact and agents or any of each of them or their substitute may lawfully do or cause to be done by virtue hereof.

 

Pursuant to the requirements of the Securities Act of 1933, this Registration Statement has been signed by the following persons in the capacities and on the dates indicated.

 

 

 

Name   Title   Date
         

/s/ Chaim Lebovits

Chaim Lebovits

 

President and Chief Executive Officer

(Principal Executive Officer)

  July 3, 2025
         

/s/ Alla Patlis

Alla Patlis

 

Interim Chief Financial Officer

(Principal Financial and Accounting Officer)

  July 3, 2025
         

/s/ Irit Arbel

Irit Arbel

  Director   July 3, 2025
         

/s/ Nir Naor

Nir Naor

  Director   July 3, 2025
         

/s/ Jacob Frenkel

Jacob Frenkel

  Director   July 3, 2025
         

/s/ Anthony Polverino

Anthony Polverino

  Director   July 3, 2025
         

/s/ Uri Yablonka

Uri Yablonka

  Director   July 3, 2025
         

/s/ Menghisteab Bairu

Menghisteab Bairu

  Director   July 3, 2025
         

/s/  Stacy Lindborg

Stacy Lindborg

  Director   July 3, 2025

 

 

FAQ

What did ContextLogic (WISH) change in the reorganization agreement?

The Board added a clause stating that the 4.9% ownership transfer restriction will expire no later than three years after the reorganization becomes effective.

Why was the amendment necessary?

Institutional Shareholder Services recommended voting against the deal because the transfer restriction had no sunset; the three-year limit removes that concern.

Does the amendment affect the economic terms of the deal?

No. The filing states that no valuation, consideration, or other economic provisions were altered.

When will shareholders vote on the revised proposal?

At the Annual Meeting scheduled for July 10, 2025.

What happens if shareholders approve the reorganization proposal?

Approval will also be deemed approval of the new "Expiration Date" definition; no further board action is required to implement it.

Where can investors read the full amended documents?

The Second A&R Agreement (Exhibit 2.1) and amended certificate (Exhibit 3.1) are available within the 8-K filing on the SEC’s EDGAR system.
Brainstorm Cell Therapeutics I

NASDAQ:BCLI

BCLI Rankings

BCLI Latest News

BCLI Latest SEC Filings

BCLI Stock Data

12.89M
6.67M
20.84%
12.49%
1.88%
Biotechnology
Biological Products, (no Disgnostic Substances)
Link
United States
NEW YORK